SOUTH SAN FRANCISCO - Septerna, Inc. (NASDAQ:SEPN), a biotechnology firm engaged in G protein-coupled receptor (GPCR) drug discovery and currently valued at $1.05 billion, today announced Gil Labrucherie as its new Chief Financial Officer. Labrucherie brings over two decades of experience in senior finance and legal roles within the biopharmaceutical sector.
The company's CEO, Jeffrey Finer, M.D., Ph.D., expressed confidence in Labrucherie's ability to contribute to Septerna's growth and the advancement of its product pipeline, including SEP-786 and other GPCR programs. Labrucherie's appointment is expected to play a critical role in scaling the organization and enhancing its financial and capital strategy. According to InvestingPro, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 10.08, though analysts expect continued losses this year.
Labrucherie's career includes leadership positions at ACELYRIN, where he led finance and business development, and Nektar Therapeutics (NASDAQ:NKTR), where he served as CFO and COO. His track record includes raising over $1.5 billion in equity capital and facilitating strategic partnerships that generated significant value. With analyst price targets ranging from $38 to $50, InvestingPro subscribers can access 7 additional key insights about Septerna's financial outlook and market position.
With a J.D. from the University of California Berkeley School of Law and a B.A. from the University of California Davis, Labrucherie is also a Chartered Financial Analyst and a member of the State Bar of California. He currently serves on the board of Rezolute (NASDAQ:RZLT), Inc.
Septerna's proprietary Native Complex Platform™ underpins its strategy to unlock the therapeutic potential of GPCRs. The company focuses on developing oral small molecule treatments in endocrinology, immunology, inflammation, and metabolic diseases. This announcement is based on a press release statement.
In other recent news, Septerna Inc has received positive evaluations from Cantor Fitzgerald, TD (TSX:TD) Cowen, and JPMorgan (NYSE:JPM), all initiating coverage with optimistic outlooks. Cantor Fitzgerald assigned an Overweight rating with a $50.00 price target to Septerna, indicating confidence in the company's growth prospects, particularly in the G protein-coupled receptors (GPCR) field. The rating was based on a detailed financial model and an expectation for the company to outperform in its sector.
TD Cowen initiated coverage with a Buy rating, highlighting promising preclinical data from Septerna's leading drug candidate, SEP-786, and the anticipated Phase 1 data and Investigational New Drug (IND) filings in 2025. JPMorgan, assigning an Overweight rating, emphasized Septerna's innovative Native Complex Platform, which enhances the development of medications targeting G Protein-Coupled Receptors (GPCRs). The lead candidate, SEP-786, developed for Hypertrophic Pyloric Stenosis (HPT), is anticipated to be a significant catalyst upon reaching clinical milestones in 2025.
All three firms highlighted Septerna's strong financial position, with a cash runway extending into the second half of 2027, expected to support ongoing research and development efforts. JPMorgan also predicts opportunities for Septerna through partnerships or licensing deals for its non-core assets. These recent developments underline the industry's confidence in Septerna's strategic focus on GPCR drug development and its ability to deliver value to shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.